Viking Theracs (VKTX) Stock: Climbing On Analyst Upgrade

Viking Therapeutics Inc (NASDAQ: VKTX) is having a strong start to the trading session this morning. However, if you’re looking for press releases or SEC filings, you’ll likely be disappointed. There has been no news released. Nonetheless, there’s a good reason for the gains. The company was the center of an analyst upgrade, exciting investors … Read more

Viking Therapeutics (VKTX) Stock: Up After Presenting Phase 2 Data

After announcing that it has presented positive clinical data, Viking Therapeutics Inc (NASDAQ: VKTX) is flying in the pre-market thous morning. The data surrounds the company’s VK2809 candidate and proved to be just what investors wanted to see. Today, we’ll talk about the data, what we’re seeing from the stock as a result, and what … Read more

Viking Therapeutics (VKTX) Stock: Continues Skyward On Clinical Data

Viking Therapeutics Inc (NASDAQ: VKTX) is having yet another overwhelmingly strong day in the market today after announcing positive clinical data from a Phase 2 clinical trial yesterday. The tremendous gains likely have to do with the massive market size the drug has the potential to tap into. Today, we’ll talk about: The treatment that’s … Read more

Viking Therapeutics (VKTX) Stock: Leading The Biotech Sector Today

Viking Therapeutics Inc (NASDAQ: VKTX) is the leader among biotechnology stocks today after the company released positive top-line data from a Phase 2 clinical study. The study was designed to assess VK2809, the company’s candidate for the treatment of NAFLD. NAFLD is a severe condition with serious unmet medical need, so the positive data is … Read more

Madrigal Pharmaceuticals (MDGL) Stock: Falling Hard On Viking Therapeutics’ News

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) is having an overwhelmingly rough start to the trading session this morning, and for good reason. The company’s experimental treatment was looked at as the first in line in NAFLD treatment. However, Viking Therapeutics (NASDAQ: VKTX) announced positive Phase 2 clinical data from VK2809, a competing drug. Of course, the … Read more

Viking Therapeutics (VKTX) Stock: Rocketing On Clinical Data

Viking Therapeutics Inc (NASDAQ: VKTX) is flying early on in the trading session this morning, and for good reason. The company announced top line results from a Phase 2 clinical trial that proved to be overwhelmingly positive. Of course, the news excited investors, sending the stock on gains in multiples. Today, we’ll talk about: The … Read more

Viking Therapeutics (VKTX) Stock: Headed For The Top On Coverage Initiation

Viking Therapeutics Inc (NASDAQ: VKTX) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company was at the center of coverage initiation with a highly trusted firm. Of course, the analyst coverage was positive, exciting investors and sending the stock on a run for the top. Today, … Read more